The French gaming giant behind Assassin’s Creed made the unusual decision to postpone its earnings release and halt share trading. Ubisoft said it would publish results “in the coming days” without providing specific reasons for the delay.
Netflix has eliminated traditional performance reviews in favor of continuous feedback and the keeper test. Employees now evaluate their managers too, creating a two-way street. The company maintains this approach builds a “talent-dense” team.
CoreWeave transformed from an Ethereum mining operation into a $50 billion AI infrastructure giant by leveraging creative financing and Nvidia’s backing. The company’s story exposes the complex financial engineering underpinning the AI boom. Its survival depends entirely on continued AI demand and N
CISO compensation packages in North America saw strong growth this year, but security budget increases hit their slowest pace in five years. The gap between top earners and median CISOs remains dramatic, with the top 1% making over $3.2 million.
Michael Burry, famous for his ‘Big Short’ bet against housing, has terminated his hedge fund’s registration. The SEC database shows Scion Asset Management’s status as terminated effective November 10. Burry hinted at “much better things” coming November 25th.
BioNTech has officially stated that its partnership with Pfizer remains unchanged following reports that Pfizer might be looking to sell its stake. The German biotech firm declined to comment on Pfizer’s potential capital market activities while emphasizing their ongoing collaboration.
In a new book excerpt, Adam Grant reflects on pandemic data interpretation and the human side of numbers. He argues we need more emotional connection to data in uncertain times.
Zilch has raised $175 million in equity and debt funding led by KKCG. The BNPL startup maintains its $2 billion valuation and plans to pursue strategic acquisitions while preparing to launch Zilch Pay next year.
Cinven’s CEO Supraj Rajagopalan faces potential disqualification from running UK companies over a pharmaceutical pricing scandal. The same deal that propelled him to leadership in 2015 now threatens to end his career. Regulators found Advanz Pharma gouged the NHS with excessive drug prices during Ci
Federal regulators are investigating proxy advisory giants ISS and Glass Lewis for potential antitrust violations. The move comes as the Trump administration considers broader action against firms influencing corporate America’s direction.
